Publications by authors named "Reaz Ahmmed"
Type 2 diabetes (T2D) is a crucial risk factor for both pancreatic cancer (PC) and kidney cancer (KC). However, effective common drugs for treating PC and/or KC patients who are also suffering from T2D are currently lacking, despite the probability of their co-occurrence. Taking disease-specific multiple drugs during the co-existence of multiple diseases may lead to adverse side effects or toxicity to the patients due to drug-drug interactions.
View Article and Find Full Text PDFGlioblastoma (GBM) is one of the most aggressive cancers due to its high mortality rate in spite of intensive treatment. It may be happened because of drug resistance against their typical receptors, since these receptor genes are often mutated by environmental stress. So identifying mutated oncodriver genes which could be used as potential drug target is essential in order to develop effective new therapeutic drugs as well as better prognosis for GBM patients.
View Article and Find Full Text PDFArticle Synopsis
- Thyroid carcinoma (THCA) is the most common endocrine cancer in the head and neck, with ongoing research investigating its genetic links and molecular mechanisms, which are still not fully understood.
- While drug therapies are the main treatment for advanced THCA, many patients develop resistance over time, highlighting the need for multi-targeted drug therapies.
- A study identified 80 differentially expressed genes related to THCA and pinpointed eight key genes (some upregulated, some downregulated) that could serve as potential biomarkers for diagnosis and prognosis.
Article Synopsis
- - Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, and while genetic changes are linked to its development, the exact mechanisms are not fully understood.
- - Drug treatments can initially be effective, but most patients develop resistance within two years, highlighting the need for multi-target therapies and the identification of key genes involved in ccRCC.
- - Research identified 133 common differentially expressed genes, narrowed them down to 54 significant ones through survival analysis, and discovered eight key genes that are strongly associated with ccRCC progression, which could inform future treatments.
Article Synopsis
- The study explores the link between Type 2 diabetes (T2D) and clear-cell renal cell carcinoma (ccRCC), with findings suggesting that both diseases share common key genes (sKGs) that may contribute to their development.
- Researchers identified 259 shared differentially expressed genes and selected ten significant sKGs that showed a connection with DNA methylation patterns that could be linked to ccRCC.
- The study also recommends three repurposable drugs, Digoxin, Imatinib, and Dovitinib, as potential treatments for patients suffering from both T2D and ccRCC, based on molecular analysis.